The FDA approved the use of TBI blood biomarkers, glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase (UCH-L1), to evaluate the utility of imaging tests in adult mTBI patients (FDA, 2018). The gene discussed is GFAP; the disease is concussion.